BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Day One Biopharmaceuticals\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Day One Biopharmaceuticals\, Inc.
 's drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04775485-2192@assetmemo.bio
DTSTAMP:20261121T005953Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Tovorafenib: Phase 2 readout est. (NCT04775485)
DESCRIPTION:Tovorafenib\, phase 2\, Glioma.\nStudy: A Study to Evaluate Tov
 orafenib in Pediatric and Young Adult Participants With Relapsed or Progre
 ssive Low-Grade Glioma and Advance Solid Tumors\nEstimated primary complet
 ion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tov
 orafenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT04775485
URL:https://assetmemo.bio/drug/tovorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05566795-2192@assetmemo.bio
DTSTAMP:20261121T005953Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tovorafenib: Phase 3 readout est. (NCT05566795)
DESCRIPTION:Tovorafenib\, phase 3\, Glioma.\nStudy: DAY101 vs. Standard of 
 Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requirin
 g First-Line Systemic Therapy (LOGGIC/FIREFLY-2)\nEstimated primary comple
 tion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tovo
 rafenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05566795
URL:https://assetmemo.bio/drug/tovorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
